Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 24, 2011

Portola secures financing for Phase III betrixaban study

Portola Pharmaceuticals has secured $89m in preferred stock financing to advance its Phase III clinical programme of betrixaban, a once-daily, oral Factor Xa inhibitor.

Portola Pharmaceuticals has secured $89m in preferred stock financing to advance its Phase III clinical programme of betrixaban, a once-daily, oral Factor Xa inhibitor.

The funds will also be used to develop PRT064445, a recombinant Factor Xa inhibitor antidote.

The company is planning to commence a Phase III programme in the first half of 2012to trial betrixaban as a way of preventing venous thromboembolism in acutely ill patients.

In collaboration with Biogen Idec, Portola will develop PRT062607, an oral Syk-specific kinase inhibitor in thrombosis.

Biogen Idec will provide Portola with an upfront payment of $45m, which includes $36m in cash and $9m in Portola equity.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU